Report : Europe Liver Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type (Laboratory Tests, Endoscopy, Imaging, Biopsy, and Others) and End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutes, and CRO Laboratories)
Blood Tests segment to dominate the Europe Liver Cancer Diagnostics Market during 2021–2028
According to a new market research study on “Europe Liver Cancer Diagnostics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type and End User” is expected to reach US$ 4,308.57 million by 2028 from US$ 2,567.59 million in 2021. The market is estimated to grow at a CAGR of 7.7% from 2021 to 2028. The report provides trends prevailing in the Europe liver cancer diagnostics market along with the drivers and restraints pertaining to the market growth. Surging prevalence of liver cancer, burgeoning emergence of new technologies, and growing demand for point-of-care testing are the major factor driving the growth of the Europe liver cancer diagnostics market. However, heavy cost of technologically advanced liver cancer diagnostic solutions hinders the growth of Europe liver cancer diagnostics market.
The Europe liver cancer diagnostics market is segmented on the basis of type, end user, and country. Based on type, the market is segmented into laboratory tests, imaging, endoscopy, biopsy, and others. In 2021, the laboratory tests segment held a larger share of the market; and the imaging segment is expected to register a higher CAGR during the forecast period. Further based on laboratory tests, the Europe liver cancer diagnostics market is segmented into blood tests and biomarkers. In 2021, the blood tests segment held the largest market share; and the same segment is expected to register the highest CAGR in the market during the forecast period. Based on end user, the market is segmented into hospitals and diagnostic laboratories, academic and research institutes, and CRO laboratories. In 2021, the hospitals and diagnostic laboratories segment held a larger share of the market; and the same segment is expected to register a higher CAGR during the forecast period. Based on country, the Europe liver cancer diagnostics market is segmented into Germany, France, the UK, Italy, Spain, and Rest of Europe. In 2021, Germany held the largest market share; and the UK is expected to grow at the fastest CAGR during the forecast period.
Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; and Perspectum are among the leading companies in the Europe liver cancer diagnostics market. For instance, Illumina, Inc. launched TruSight oncology test for assessing multiple tumor genes and biomarkers. The TruSight test will soon begin its global launch in Europe, assesses the tumor genes and biomarkers to reveal the specific molecular profile of a patient’s cancer, helping to inform precision medicine decisions.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com